By Finance Pulse in RMD —

ResMed Shares Fall 4% After FDA Approves Eli Lilly's Zepbound

ResMed stock drops 4% as Eli Lilly's Zepbound receives FDA approval for sleep apnea, impacting the competitive landscape.

A dynamic stock market chart with ResMed and Eli Lilly logos, set against a backdrop of FDA approval
ResMed Shares Fall 4% After FDA Approves Eli Lilly's Zepbound

Shares of ResMed fell roughly 4% following FDA approval of Eli Lilly's Zepbound.

Source